+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating GB-0895 as an additional therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and other standard asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the efficacy and safety of GB-0895 in improving health outcomes for this population, with an optional open-label extension phase. Participants will receive subcutaneous injections of either GB-0895 or a placebo every six months over a 52-week treatment period. The study includes a screening and run-in phase lasting up to five weeks before treatment starts. After the treatment phase, participants will enter a follow-up period lasting from week 52 to week 90 or may opt to join an open-label extension lasting until week 142. During the study, participants will be regularly assessed for asthma exacerbations, lung function changes, quality of life, symptom control, and safety measures including lab tests, vital signs, and ECGs. Researchers will monitor the annualized asthma exacerbation rate as the primary outcome and evaluate additional respiratory and quality of life assessments. The total participation time may extend up to nearly three years for those in the optional open-label extension.

Age: 12Years - 80YearsAll GendersPhase 3
134 locations